BioPharma Dive November 30, 2018
Jacob Bell

The chilly first months of 2018 brought with them a flurry of biopharma deals. Celgene in January snapped up CAR-T specialist Juno Therapeutics for $9 billion on the same day Sanofi announced it would be taking over hemophilia drugmaker Bioverativ for $11 billion. By springtime, the industry saw one of its largest acquisitions ever in Takeda’s $62 billion purchase of Shire.

Though the M&A storm has calmed down slightly, 2019 should be another active year for life sciences dealmaking — particularly in the biotech, payer, outsourced services and healthcare IT arenas, according to some major investment bankers presenting at the Forbes Healthcare Summit in New York.

“It’s...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Technology, Trends
In the Pipeline: LifeSpire of Virginia Announces $80M Renovation Plan; Oak Trace Completes Multiphase $112M Campus Redevelopment
Boston Scientific’s $3.7B Axonics buy tops list of medtech M&A in 2024
Digital health venture capital deals stagnate
Ascension continues selling spree
Acadia Executes 3 New Acquisitions, Fueling 2024 Growth Strategy

Share This Article